RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa
Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)
Doctors at several eye research foundations are seeking patients with Advanced Retinal Pigmentosa. The drug uses a genetic editing tool, delivered only within the retina, designed to insert a gene for channelrhodopsin-2, to create new photosensors in retinal ganglion cells and potentially restore vision.
Treatment will involve a single injection surgery to the retina at the back of the eye, then follow up for 2 years.
- Be 18 years of age and older
- Meet genetic screening requirements specific to the study aim
- Not have participated in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months
THE STUDY INVOLVES:
- Screening before the treatment.
- A single injection of the genetic therapy to the retina at the back of the eye.
- Follow up for 2 years.
LOCATIONS AND CONTACTS:
The study locations include:
Duke Eye Center, Duke University Medical Center in Durham, NC. Map.
Cincinnati Eye Institute in Cincinnati, OH, Map.
University of California Dept. of Ophthalmology in San Francisco, CA. Map.
Retina Foundation of the Southwest in Dallas, TX. Map.